Member Info for EmeraldCarrots

So we have:-

1. MT-RNR1's in use in the NHS.

"nine Group 1 sites live, with a further five Group 2 sites phased to go-live from May 2025".

- I guess 12 sites with 2Nr. machines. So 24 Nr.

I'm assuming 2 sites still not up and runnning.

2. CYP2C19's in use in the NHS. ? Nr.

I guess 15 Nr.

3. MT-RNR1's in use internationally. ? Nr.

I guess 25Nr.

4. CYP2C19's in use internationally. ? Nr.

I guess 15 Nr.

========================

Just that adds up to 79 Nr.

I have read that every baby moved to neonatal is given antibiotics as a precaution.

So once all the MT-RNR1 sites are up and running there will be 14 neonatal wards testing every baby that is admitted.

That will be a lot. A lot of consumables too.

Anyone else know how many?

All IMHO.

Lab test results in the hope that they drop dead while waiting for the results? I must admit this would be a sure way of saving money. Would free up a bed straight away and no more tests to pay for at all. LOL!

Https://www.nice.org.uk/guidance/dg59/chapter/1-Recommendations

Just look what it says here:-

"Implementing laboratory-based CYP2C19 genotype testing for everyone who has a stroke or TIA would result in a large population being tested, which may require testing capacity to be scaled up over time. When implementing testing, commissioners may wish to consider:

1. A phased rollout with testing initially offered to people with a higher risk of stroke recurrence who could benefit most from it, such as people who have had a non‑minor stroke

2. Point-of-care testing as an alternative if laboratory-based testing is not feasible at this scale, or while capacity for laboratory-based testing is increased.

What is the *ucking point in giving everyone who has a stroke this lab test that is a) not even available sometimes and b) Takes far too long anyway! How stupid is that? Beggars belief. We pay people to produce this sort of rubbish. NICE should be scrapped and replaced with a more streamlined system that works.

All IMHO.

Https://www.nice.org.uk/guidance/dg59/chapter/1-Recommendations

Just look what it says here:-

"Implementing laboratory-based CYP2C19 genotype testing for everyone who has a stroke or TIA would result in a large population being tested, which may require testing capacity to be scaled up over time. When implementing testing, commissioners may wish to consider:

1. A phased rollout with testing initially offered to people with a higher risk of stroke recurrence who could benefit most from it, such as people who have had a non‑minor stroke

2. Point-of-care testing as an alternative if laboratory-based testing is not feasible at this scale, or while capacity for laboratory-based testing is increased.

Fully grown male African Elephant in the room........... Lab testing involves a blood draw, normally a courier to get the sample there and so many hours and usually 2-5 days for the result. The genedive does not need a blood sample can be done immediately and gives the result in an hour. Honestly, do we pay these people to produce this nonsense?

All IMHO.

So far thay have had five weeks to publish this implementation guide. It's a joke. Most of these people would not survive 5 minutes working for a private Company. IMHO most of them have an easy life working for the NHS.

Https://www.nice.org.uk/guidance/dg59

"Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.

NICE is working with NHS England, who are delivering a national pilot to produce an implementation guide for providers and information to support future commissioning decisions. The pilot ran from October 2024 to May 2025 and the results from this are now being reviewed. ".

========================

Delay may be because NHS England is being scrapped? LOL! That could be a issue?

"Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.

NICE is working with NHS England, who are delivering a national pilot to produce an implementation guide for providers and information to support future commissioning decisions. The pilot ran from October 2024 to May 2025 and the results from this are now being reviewed. ".

=========================

Delay may be because NHS England is being scrapped?

Publishing it? If it real, or made up on here by posters?

Unaware or badly advised about the importance of getting FDA clearance for the sale of MT-RNR1 in the USA. We are A YEAR on from this:-

https://www.lse.co.uk/rns/GDR/breakthrough-device-designation-from-the-us-fda-2zclfstav7guqaq.html

Beggars belief. If were not for the fact they can apparently use data from the NHS trials in the UK for the FDA application I could understand. I think not giving this priority is a massive error of judgement by the Directors. A monumental mistake of epic proportions.

All IMHO.

Anyone even with a small understanding of the stock market knows the MT-RNR1 FDA application to sell the machine in the USA is key.

- Anyone except the Directors of Genedrive and their advisors it seems. Are they clueless?

So am I correct in saying a positive "Trading update" is certain considering all the new orders!

Interim results to 31 Dec 2024.:-

· Revenue and other income of £0.35m (H1 2023/4: £0.24m)

· R&D spend of £2.1m (H1 2023/4: £1.9m)

· Operating loss of £2.6m (H1 2023/4: £2.4m)

· Cash of £2.1m as at 31 December 2024 (30 June 2024: £5.2m)

· Cash of £1m as at 20 March 2025

· Equity fundraise of up to £1.25m announced (see separate announcement today)

What Angle really needs is a cancer drug trial that uses dual analysis.

Or uses one or both of the assays Angle produced for Astrazeneca.

Gobi7.

This RNS's good point is simply cancer clusters need to be investigated more to see if breaking up clusters reduces or stops cancer spread. As Parsortix can catch live intact cancer clusters that are uncontaminated more sales of the machine to labs are likely for research.

What Angle really needs is a cancer drug trial that uses dual analysis.

GordonGecko123.

And yet it's down again.. Doesn't say mucb with all these people saying how good parsortix is that AN can't seem to sell it to anyone.

Something very wrong here and with this company. Such promise and fails to deliver.

==================================

I think AN is not a good sales person. He's good at the tech of that there is no doubt, and explaining it. So he is an assett. However he shoud hand the sales side to someone else.

This latest RNS is more reason labs should be buying and using the Parsortix machine. It can as we know catch live, intact cancer cell clusters uncontaminated ideal for DAN, or any other type of analysis.

All IMHO.

Mr Hendrix.

"will be enough to send the share price multiplying up from here 10-15 times".

=====================================

If that happens I would make over £200,000. But here, back on earth having not taken any drugs I think we should say more like:-

1. On MT-RNR1 FDA application in say 3.5p a share tops.

2. On MT-RNR1 FDA clearance 8p a share tops.

But what is they do both applications at once! That would be interesting.

All IMHO of course.

AND even if (unlikely if you ask me) they don't have the "live use" data they could forward it in a few months as FDA processing the application will take some months, around 3. It's incredily frustrating.

If you have the data from the use in the at least 9 NHS neonatal words how difficult can it be to do an FDA application for the MT-RNR1?

It's got to happen soon, assuming they have a clue what they are doing. I'm beginning to wonder to be honest.

Spantrout.

"And yet despite the BoD showing at a public forum application would be end fy26 u refuse to listen".

======================================

I don't buy that at all. I think they said that to be ulta cautious and keep shareholders like me from going on about it. Things have progressed too. They have at least 9 neonatal wards and possibly 14 gathering the required data daily, 7 days a week. I'm expecting a surprise announcement anytime to say the application for the MT-RNR1 is in. Then if they need to do a placing it will be for North of 2.5p.

We will see........

All IMHO.

The MT-RNR1 can be sold in the USA. Market there over $100 million a year.

AI Overview.

"Approximately 1 in 7 babies born in England, Scotland, and Wales require neonatal care. This means roughly 105,000 out of 750,000 babies need specialist care in a hospital. These babies are either born prematurely, are sick, or have a low birth weight. ".

=================================================

So, assuming eventually is every baby who needs neonatal care is tested it would cost about 105,000 x £115 = £12 million.